Peter Greenleaf

Peter Greenleaf

Voorzitter bij
Maryland Venture Fund

Vermogen: 29 M $ op 31-05-2026

56 jaar
Health Technology
Finance
Commercial Services

Profiel

Peter S.
Greenleaf
is Chairman at Maryland Venture Fund, Chairman at Pelthos Therapeutics, Inc., Chairman at Revolo Biotherapeutics Ltd. since 2020, and holds an Advisory role at Petrichor Healthcare Capital Management LP.
Former roles include President, Chief Executive Officer & Director at Histogenics Corp.
(2013–2014); Chairman & Chief Executive Officer at Sucampo Pharmaceuticals LLC (2016–2018);.
President, Chief Executive Officer & Director at Aurinia Pharmaceuticals, Inc. (2019–2026); Chairman at BioDelivery Sciences International, Inc. (2018–2022); Independent Director at Antares Pharma, Inc. (2018–2022); Independent Director at Mast Therapeutics, Inc.; Director at Oldtech, Inc.; Director at Kiora Pharmaceuticals, Inc. (2018–2020); Director at Biotechnology Innovation Organization; Director at Melinta Subsidiary Corp.; Director at Tech Council of Maryland, Inc.; Director at LigoCyte Pharmaceuticals, Inc.; Independent Director at Mirna Therapeutics, Inc.; Director at Corridor Pharmaceuticals, Inc.; Director at Savara, Inc.; Director at OS Therapies, Inc.; Director at Avalo Therapeutics, Inc. (2019–2020); Director at Pharmaceutical Research & Manufacturers of America; Director at ValenzaBio, Inc.; Senior Vice President-Remicade Franchise at Centocor, Inc. (1998–2006); President at MedImmune LLC (2006–2013); Principal at US Healthcare, Inc.; Principal at Hallmark Cards, Inc.; President at MedImmune Ventures, Inc. (2010–2013); Principal at Roche Diagnostics Corp.
(1996–1998); Trustee at The University of Maryland Baltimore Foundation, Inc.; District Manager at Boehringer Mannheim GmbH (1996–1998); President at AstraZeneca PLC (2006–2013).
Education includes an MBA from St. Joseph's University and undergraduate studies at Western Connecticut State University.

Bekende belangen in openbare bedrijven

OndernemingDatumAantal aandelenTotale waardeWaarderingsdatum
02-03-2026 1.840.379 ( 1,43% ) 28 M $ 31-05-2026
0,71%
02-04-2026 24.681 ( 0,71% ) 653 306 $ 31-05-2026

Laatste nieuws over Peter Greenleaf

Actieve functies van Peter Greenleaf

BedrijvenFunctieBegin
Voorzitter -
Voorzitter 17-12-2020
Consultant / Adviseur -

Eerdere bekende functies van Peter Greenleaf

BedrijvenFunctieEinde
AURINIA PHARMACEUTICALS INC. Algemeen Directeur 23-03-2026
ANTARES PHARMA, INC. Directeur/Bestuurslid 24-05-2022
BIODELIVERY SCIENCES INTERNATIONAL, INC. Voorzitter 22-03-2022
AVALO THERAPEUTICS, INC. Algemeen Directeur 15-04-2019
KIORA PHARMACEUTICALS, INC. Directeur/Bestuurslid 03-01-2020
Ervaring van Peter Greenleaf in detail bekijken

Opleiding van Peter Greenleaf

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

69

Eerstegraads connecties

33

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit33

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Consumer Non-Durables

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Commercial Services

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Miscellaneous

Finance

Commercial Services

Health Technology

Health Technology

Health Technology

Boehringer Mannheim GmbH

Health Technology

Health Technology

Finance

Health Technology

Health Technology

  1. Beurs
  2. Insiders
  3. Peter Greenleaf
-40 %: uitzonderlijke verlenging
d
:
:
PROFITEER NU